It is possible that effective short-term RT regimens promote transient production of IFN-α/β by DCs and of IFN-γ by T cells, which temporarily engage STAT1 and/or other STAT molecules in both host cells (including immune cells) and tumor cells to trigger protective anti-tumor responses. The gene discussed is IFNA2; the disease is neoplasm.